Table 4.
Recurrences in patients treated with chemoradiotherapy
| PS | Location | ER | RT field | Dose | Recurrence site | DFS | Treatment for recurrence |
|---|---|---|---|---|---|---|---|
| 0 | Mt | − | ENI | 60.0 | Local | 0 | Surgery |
| 1 | Mt | + | ENI | 28.0 | Lung | 6.1 | Surgery |
| 0 | Ut | − | Non-ENI | 40.0 | Local | 7.2 | ESD |
| 0 | Mt | + | ENI | 40.0 | #104R | 13.1 | Chemotherapy |
| 0 | Lt | + | ENI | 39.6 | #3, #7 | 15.3 | Surgery |
| 0 | Ut | + | ENI | 50.4 | #101R | 19.8 | Chemotherapy |
| 0 | Mt | + | ENI | 40.0 | #109R | 22.5 | Chemotherapy |
| 0 | Mt | + | ENI | 39.6 | #104R | 28.5 | Chemotherapy |
| 0 | Mt | + | ENI | 65.0 | #104R | 30.7 | Chemotherapy |
| 0 | Mt | + | Non-ENI | 40.0 | #104R | 31.0 | Chemotherapy |
| 0 | Mt | + | ENI | 39.6 | Local | 43.2 | ESD |
| 1 | Lt | − | Non-ENI | 65.0 | #106recR | 58.3 | Chemotherapy |
| 0 | Mt | + | ENI | 40.0 | Local | 75.1 | ESD |
Lymph node metastasis was recorded according to the Japanese Society for Esophageal Diseases classification of esophageal cancer, 10th edition. #104: supraclavicular LNs (lymph nodes), #3: LNs along the lesser curvature, #7: LNs along the left gastric artery, #101: cervical paraesophageal LNs, #109: main bronchus LNs, #106rec: recurrent nerve LNs. DFS disease-free survival (months), Dose radiotherapy dose (Gy), ER endoscopic resection, ESD endoscopic submucosal dissection, Lt lower thoracic esophagus, Mt middle thoracic esophagus, PS Performance status, RT field radiotherapy field, Ut upper thoracic esophagus